Obesity Drug Liraglutide Demonstrates Weight Loss

Article

According to data presented at ObesityWeek 2014, 9 of 10 obese participants in the phase 3 SCALE Obesity and Prediabetes study lost weight with Novo Nordisk's liraglutide treatment alongside diet and exercise, compared with 65% receiving placebo.

According to data presented at ObesityWeek 2014, 9 of 10 obese participants in the phase 3 SCALE Obesity and Prediabetes study lost weight with Novo Nordisk’s liraglutide treatment alongside diet and exercise, compared with 65% receiving placebo.

In the trial, 3731 overweight or obese patients without diabetes were randomized to receive placebo or liraglutide 3 mg in combination with diet and exercise.

After 56 weeks, those taking liraglutide showed a significantly greater weight loss of 9.2%, compared with a 3.5% weight reduction among those taking placebo. In addition to losing more weight, the liraglutide group reported improvements in health-related quality of life, which was linked to better physical function.

"Obesity is more than a disease of excess weight. We know that people with obesity may experience increased physical and mental health problems, as well as a reduced quality of life," said study investigator Ken Fujioka, head of the Department of Nutrition and Metabolic Research at Scripps Clinic, in a press release. "It is encouraging to see data suggesting that the weight loss benefits of liraglutide 3 mg are associated with improved health-related quality of life for people with obesity."

According to Novo Nordisk, liraglutide is a once-daily, glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to a naturally occurring hormone released after food intake. Like that human GLP-1, liraglutide reduces hunger and increases feelings of fullness after meals.

Liraglutide is an investigational product, as neither the FDA nor the European Medicines Agency has approved it.

Related Videos
Opill manufacturing | Perrigo
Healthy food selection - Image credit: Alexander Raths | stock.adobe.com
Image Credit: Adobe Stock - nataliaderiabina
© 2024 MJH Life Sciences

All rights reserved.